The Normal Semaglutide Dosage — and Why the Answer Surprises Most People

The myth: the starting dose is the dose you stay on

The question our prescribers field most often goes something like this: "I've been on 0.25 mg for three weeks and nothing's happening, am I on the right amount?" The short answer is yes, almost certainly. The starting dose of semaglutide is not a therapeutic dose in the usual sense. Its job is to acclimatise your digestive system to the medicine, slowing gastric emptying and activating GLP-1 receptors causes nausea in a lot of people, and beginning low reduces that sharply.

Most people see modest or no weight change at 0.25 mg, and that is expected. Moving to 0.5 mg after four weeks, then 1.0 mg, then 1.7 mg, and finally 2.4 mg (each step roughly four weeks apart) is the licensed escalation path outlined in the Wegovy summary of product characteristics on the electronic Medicines Compendium (eMC). If the 2.4 mg dose is poorly tolerated, a prescriber may suggest staying at 1.7 mg for longer rather than pushing through. That is a clinical call, not a shortcut.

The practical check worth doing: before each weekly injection, look at the dose setting on your pen. If you are not sure whether your current pen matches what your prescriber intended, contact the prescribing team before injecting rather than guessing. Takes under a minute and removes real risk.

What counts as the normal maintenance dose, including the 7.2 mg option

For most people on Wegovy, 2.4 mg once weekly is the standard maintenance dose and the one used in the major weight-loss trials. The STEP 1 trial (published in the New England Journal of Medicine) reported an average weight reduction of around 15% over 68 weeks at this dose, alongside lifestyle support, in adults without diabetes. That gives a reasonable real-world benchmark, though individual results vary considerably.

In January 2026 the MHRA approved a higher maintenance dose of 7.2 mg, initially delivered as three 2.4 mg pens in the same week. On 14 April 2026, a dedicated single-dose 7.2 mg pen was approved, one injection, pre-set, no dose adjustment needed on the device itself. Trials at this higher dose reported around 20.7% average weight loss over 72 weeks, narrowing the gap with tirzepatide's headline figures. The 7.2 mg option is licensed for adults with a BMI of 30 or above; it is not available for lower BMI thresholds or for cardiovascular indications. If you want to understand how the maximum semaglutide dose is determined, that page covers the 7.2 mg approval and what it means in practice.

The titration path to 7.2 mg still begins at 0.25 mg. You cannot start at the top.

Semaglutide dosage in diabetes versus weight management, they are not the same

This distinction matters more than most people realise. Ozempic contains semaglutide at doses of 0.25 mg, 0.5 mg, 1.0 mg and 2.0 mg, but it is licensed for type 2 diabetes management, not weight loss. The semaglutide dosage for type 2 diabetes follows a different schedule, is prescribed for a different clinical purpose, and should not be conflated with the Wegovy weight-management schedule even though the active ingredient is identical. Rybelsus, the oral semaglutide tablet for diabetes, uses doses of 3 mg, 7 mg and 14 mg, none of which feature in the weight-management titration ladder.

The Wegovy tablet (oral semaglutide for weight loss, approved by the MHRA on 11 June 2026) uses an entirely different set of doses again: 1.5 mg, 4 mg, 9 mg and 25 mg. Those numbers reflect how oral bioavailability differs from subcutaneous injection, not a higher potency. If you are comparing your dose to something you have read elsewhere, the first question is always: which product, which indication?

A fuller breakdown of the Wegovy injection schedule, including what happens if you need to pause treatment, is covered in the semaglutide dosage guide. For the specific question of how dosing shifts when the goal is fat loss rather than diabetes control, the semaglutide dosage for weight loss page goes into the evidence in more detail.

What influences which dose a prescriber chooses for you

The licensed schedule is a framework, not a guarantee that every patient reaches 2.4 mg. Prescribers assess tolerability at each step. Persistent nausea, vomiting or other gastrointestinal effects might mean staying at a lower dose for an extra four weeks, or in some cases not escalating further. For most people these effects ease after the first week or two at a new level, the NHS semaglutide page describes the common side-effect profile in plain terms and is worth reading alongside your patient information leaflet.

Body weight, any concurrent conditions, and other medicines can all influence how the prescriber approaches your specific dose. That is why the consultation process matters: a prescriber reviewing your full health picture will make a more informed decision than a dose chosen off a chart. Dose increases at regulated online services require evidence of your current dose and weight before any change is authorised, that is a clinical safeguard, not a bureaucratic hurdle.

If you are at an earlier stage and want to see how the whole Wegovy treatment overview fits together, the Wegovy doses page maps the available strengths and pens. To explore whether treatment might suit you, a free consultation with our prescribers is the natural next step, and you can start that conversation here.